Synaffix B.V. and Chong Kun Dang Pharm have entered a licensing agreement, granting CKD access to Synaffix's proprietary Antibody-Drug Conjugate technologies to enhance its oncology pipeline.
Information on the Target
Synaffix B.V. is a biotechnology firm specializing in the commercialization of its clinical-stage platform technology aimed at producing antibody-drug conjugates (ADCs) that exhibit a superior therapeutic index. The company is distinguished for its proprietary technologies, including GlycoConnect™, HydraSpace™, and the toxSYN™ platform, which enhance the development of targeted cancer therapies.
The recent licensing agreement with Chong Kun Dang Pharm marks a significant milestone for Synaffix in expanding its reach within the biopharmaceutical sector. This partnership will enable CKD to incorporate Synaffix’s unique ADC technologies into their existing drug development pipeline, potentially contributing to innovative treatment options in oncology.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in South Korea
South Korea boasts a rapidly growing pharmaceutical industry recognized for its strong focus on research and development (R&D) and innovation. With a ro
Similar Deals
LG CNS → 차바이오텍 (Cha Bio Tech)
2023
Pathway Investment → Vuno
2023
Hanwha General Insurance, Hanwha Life → Cha Bio Group
LG CNS → 차바이오그룹 (CHA Bio Group)
Omega Healthcare Investors, Inc. → MedaSync
2026
Chong Kun Dang Pharm
invested in
Synaffix B.V.
in 2023
in a Strategic Partnership deal